Condition: Urothelial Carcinoma · Urothelial Carcinoma Bladder · Urothelial Carcinoma Recurrent · Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced setting.
This description comes directly from the study's public registry record.
Jia Wang · +8617356547673 · jia.wang1@mabwell.com
Always discuss trial participation with your own doctor first.
| Hunan Tumor Hospital | Changsha, Hunan, China | Recruiting |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06823427